Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles
Barbara Colzani,1,* Laura Pandolfi,1,* Ada Hoti,1 Pietro Alessandro Iovene,1 Antonino Natalello,1 Svetlana Avvakumova,1 Miriam Colombo,1 Davide Prosperi1,2 1Department of Biotechnology and Biosciences, University of Milano Bicocca, Milano, Italy; 2Nanomedicine Laboratory, ICS Maugeri S. p. A. SB, P...
Guardado en:
Autores principales: | Colzani B, Pandolfi L, Hoti A, Iovene PA, Natalello A, Avvakumova S, Colombo M, Prosperi D |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7841875efdfd460e843d809544d49318 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab
por: Nathalie I. Bouwer, et al.
Publicado: (2021) -
The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study
por: Andrea Villasco, et al.
Publicado: (2021) -
Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells
por: Rodríguez-Serrano F, et al.
Publicado: (2016) -
Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle
por: Zhang C, et al.
Publicado: (2020) -
Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer
por: Rodallec A, et al.
Publicado: (2018)